Inhibrx (NASDAQ:INBX) versus Cognition Therapeutics (NASDAQ:CGTX) Head to Head Review

Cognition Therapeutics (NASDAQ:CGTX) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Institutional and Insider Ownership

43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cognition Therapeutics and Inhibrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-150.93%	-100.82%
Inhibrx	N/A	-113.74%	-80.56%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cognition Therapeutics and Inhibrx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	0	2	4	0	2.67
Inhibrx	0	2	0	0	2.00

Cognition Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 1,900.00%. Given Cognition Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than Inhibrx.

Valuation & Earnings

This table compares Cognition Therapeutics and Inhibrx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$25.79 million	($0.97)	-0.41
Inhibrx	$1.57 million	139.22	-$154.96 million	N/A	N/A

Cognition Therapeutics has higher earnings, but lower revenue than Inhibrx.

Summary

Inhibrx beats Cognition Therapeutics on 5 of the 9 factors compared between the two stocks.

About Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

About Inhibrx

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.